CV
NASDAQCapsoVision Inc.
CapsoVision Inc. (CV) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for CV, including 1 press release or news item, 1 earnings update and 1 13D/G filing. The most recent was published Nov 4, 2026.
CV rankings
Financial highlights
Full financials- Revenue, TTM
- $13.89M
- Revenue growth
- +11.0%
- Net income, TTM
- -$29.83M
- Net margin
- -214.7%
- Free cash flow, TTM
- -$27.89M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39-67%
2026-05-172026-11-08
Mix1990d
- SEC Filings8(42%)
- Insider4(21%)
- Other3(16%)
- Earnings2(11%)
- Analyst1(5%)
- 13D/G1(5%)
Activity · 52 weeks7438 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.SCHEDULE 13G/A - CapsoVision, Inc (0001378325) (Subject)
- PRCapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026SARATOGA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release third quarter 2026 financial results on Thursday, November 12, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 2841803. The live and archived webcast of
- PRCapsoVision to Present at the 20th Annual LD Micro Main EventSARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Format: Company Presentation and 1x1 Investor Meetings Date/Time: Wednesday, October 21, 2026, at 9:00–9:25 am PT A webcast of the presentation will be streamed live at the
- SECSEC Form 8-K filed by CapsoVision Inc.8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®SARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Food and Drug Administration (FDA) on September 25, 2026. AI Highlights is designed to support physicians in the review of small bowel capsule endoscopy studies collected from adult and pediatric patients (over two years of age) in whom the study was performed due to suspected small bowel bleeding, specifically to reduce the time taken to review capsule endoscopy
- INSIDERLarge owner Harari Eliyahou Et Al bought $9,999,999 worth of shares (1,757,469 units at $5.69) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERAmendment: Large owner Shen Ching Hang disposed of 3,991,606 shares and acquired 3,991,606 shares, closing all direct ownership in the company (SEC Form 4)4/A - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERAmendment: Large owner Shen Ching Hang bought $4,999,996 worth of shares (878,734 units at $5.69) (SEC Form 4)4/A - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERLarge owner Shen Ching Hang bought $4,999,996 worth of shares (878,734 units at $5.69) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- SECSEC Form 8-K filed by CapsoVision Inc.8-K - CapsoVision, Inc (0001378325) (Filer)
- SECSEC Form 424B5 filed by CapsoVision Inc.424B5 - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision to Participate in Upcoming Investor ConferencesSARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City) Format: On-demand Company Presentation and 1x1 Investor MeetingsDate/Time: On-demand Company Presentation – Friday, September 11, 2026, beginning at 7:00 a
- ANALYSTRoth Capital resumed coverage on CapsoVision with a new price targetRoth Capital resumed coverage of CapsoVision with a rating of Buy and set a new price target of $9.00
- SECSEC Form EFFECT filed by CapsoVision Inc.EFFECT - CapsoVision, Inc (0001378325) (Filer)
- SECSEC Form 424B5 filed by CapsoVision Inc.424B5 - CapsoVision, Inc (0001378325) (Filer)
- SECSEC Form S-3 filed by CapsoVision Inc.S-3 - CapsoVision, Inc (0001378325) (Filer)
- SECSEC Form 10-Q filed by CapsoVision Inc.10-Q - CapsoVision, Inc (0001378325) (Filer)
- SECCapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Reports Second Quarter 2026 Financial ResultsSARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026. Recent Highlights Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small bowel capsule endoscopy studies using the Caps
- PRCapsoVision® Announces International Launch of AI HighlightsSARATOGA, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView® and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and revi
- PRCapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 9178774. The live and archived webcast of t
- INSIDERLarge owner Harari Eliyahou Et Al bought $410,988 worth of shares (61,068 units at $6.73) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERLarge owner Harari Eliyahou Et Al bought $495,117 worth of shares (81,300 units at $6.09) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERLarge owner Harari Eliyahou Et Al bought $101,811 worth of shares (13,850 units at $7.35) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Director Shields David Stanley4 - CapsoVision, Inc (0001378325) (Issuer)
CV FAQ
9 questionsWhat is the latest news on CV?
In the last 30 days Quantisnow tracked 3 wire items for CV: 1 press release or news item, 1 earnings update and 1 13D/G filing. The most recent was published on November 4, 2026.What is CV revenue?
CapsoVision Inc. (CV) reported $13.89M of revenue for the twelve months ended Jun 30, 2026. That is up 11.0% from the year before. Revenue for fiscal 2025 was $13.55M.Is CV profitable?
No. CapsoVision Inc. reported a net loss of $29.83M for the twelve months ended Jun 30, 2026.Where does CV stock trade?
CapsoVision Inc. (CV) is listed on NASDAQ.What sector and industry is CV in?
CapsoVision Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did CapsoVision Inc. go public?
CapsoVision Inc. (CV) completed its IPO in 2025.What are analysts saying about CV?
CapsoVision Inc. has had 3 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $9.00 price target on 2026-08-28. Recent price targets range from $5.00 to $9.00.What companies are similar to CV?
Notable peers in the same industry include AXGN (Axogen Inc.), TMDX (TransMedics Group Inc.), MDT (Medtronic plc.), LIVN (LivaNova PLC), CBLL (CeriBell Inc.). Compare CV side-by-side with any of them on Quantisnow.How can I track CV on Quantisnow?
Quantisnow aggregates CapsoVision Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CV to receive live email and push alerts on every new disclosure.